1Evans JF,Kargman SL.Cancer and cyclooxygenase-2 (COX-2) Inhibition.Curr Pharm Des,2004,10(6):627-634.
2Morita I.Distinct functions of COX-1 and COX-2.Prostaglandins Other Lipid Mediat,2002,68(69):165-175.
3Soslow RA,Dannenberg AJ,Rush D,et al.COX-2 is expressed in human pulmonary,colonic,and mammary tumors.Cancer,2000,89(12):2637-2645.
4Khuri FR,Wu H J,Lee J,et al.Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.Clin Cancer Res,2001,7(4):861-867.
5Hida T,Kozaki K,Muramatsu H,et al.Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.Clin Cancer Res,2000,6(5):2006-2011.
6Tsubouchi Y,Filippov,Couve A,et al.Heteromeric assembly of GABABR1 and GABABR2 receptor subunits inhibits Ca2+ current in sympathetic neurons.Anticancer Res,2000,20(8):2867-2872.
7Altorki NK,Keresztes RS,Port JL,et al.Celecoxib,a selective cyclo-oxygenase-2 inhibitor,enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.J Clin Oncol,2003,21(14):2631-2632.
8Pyo H,Choy H,Amorino GP,et al.A selective cyclooxygenase-2 inhibitor,NS-398,enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.Clin Cancer Res,2001,7(5):2998-3005.
9Vokes EE,Choy H.Targeted therapies for stage Ⅲ non-small cell lung cancer: integration in the combined modality setting.Lung Cancer,2003,41(8):S115-121.
